Pharmacotherapy of Polycystic Ovary Syndrome: An Update

January 2011 in “ Fundamental & Clinical Pharmacology ”

Lekha Saha, Sharonjeet Kaur, Pradip Kumar Saha

TLDR New treatments for PCOS show promise, but no current medication treats all aspects of the condition.

The document from 2011 reviews pharmacological treatments for polycystic ovary syndrome (PCOS), including oral contraceptives, antiandrogens, clomiphene, letrozole, gonadotropins, and ovarian drilling for various symptoms and complications of PCOS. Insulin sensitizers like metformin and thiazolidinediones are discussed for improving insulin sensitivity and ovulation rates, but their effectiveness in reproductive outcomes is limited. Newer treatments such as melatonin and N-acetyl cysteine show promise in managing PCOS symptoms. Acarbose is mentioned for its potential benefits in reducing insulin resistance and hyperandrogenism, while statins may improve hyperandrogenemia and cardiovascular risks. Despite the range of treatments, none fully address all aspects of PCOS, indicating a need for ongoing research and development of more effective therapies.

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Research cited in this study

6 / 6 results

research Use of Ethinylestradiol/Drospirenone Combination in Patients with Polycystic Ovary Syndrome

52 citations , April 2008 in “Therapeutics and clinical risk management”

The birth control combination of ethinylestradiol and drospirenone helps treat symptoms of polycystic ovary syndrome.

research Relative Prevalence of Different Androgen Excess Disorders in 950 Women Referred Because of Clinical Hyperandrogenism

352 citations , January 2006 in “The Journal of Clinical Endocrinology and Metabolism”

Most women referred for excess male hormone symptoms had polycystic ovary syndrome (PCOS), with other conditions being less common.

research Health Care-Related Economic Burden of Polycystic Ovary Syndrome During the Reproductive Life Span

414 citations , August 2005 in “The Journal of Clinical Endocrinology and Metabolism”

Polycystic ovary syndrome costs the U.S. over $4 billion a year, mainly from treating related health issues.

research A Randomized, Placebo-Controlled Trial of 5% and 2% Topical Minoxidil Solutions in the Treatment of Female Pattern Hair Loss

219 citations , March 2004 in “Journal of The American Academy of Dermatology”

5% and 2% minoxidil solutions effectively promote hair growth and reduce hair loss, with 5% being slightly more effective but having more side effects.

research Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome

4809 citations , January 2004 in “Fertility and Sterility”

The 2003 consensus updated PCOS diagnosis criteria and highlighted increased risks of diabetes and heart disease for those affected.

research Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome (PCOS)

4025 citations , December 2003 in “Human Reproduction”

The 2003 consensus updated PCOS diagnosis criteria and linked PCOS to higher risks of diabetes and heart problems, recommending lifestyle changes to lower these risks.